RedHill Biopharma Ltd.RDHL
| Dec 31,
2017 | Dec 31,
2018 | Dec 31,
2019 | Dec 31,
2020 | Dec 31,
2021 | Dec 31,
2022 | Dec 31,
2023 | Dec 31,
2024 |
|---|
| Income (loss) | -46 | -39 | -42 | -76 | -98 | -72 | 24 | -8 |
|---|
| Adjustments for share-based payments | 2 | 3 | 3 | 4 | 10 | 6 | 2 | 1 |
|---|
| Depreciation | 0 | 0 | 1 | 2 | 2 | 2 | 1 | 1 |
|---|
| Amortization of intangible assets | - | - | 0 | - | - | - | 1 | 0 |
|---|
| Gains from the transfer of rights in Movantik and extinguishment of debt obligations, see below | - | - | - | - | - | - | -56 | - |
|---|
| Gains From Early Termination Of Leases And Impairment Of Fixed Assets | - | - | - | - | - | - | - | -0 |
|---|
| Adjustment For Non Cash Loss From Global Termination Agreement. | - | - | - | - | - | - | - | 2 |
|---|
| Fair value (gains) losses on derivative financial instruments, recognition of day 1 loss and changes in royalty obligation | - | - | - | - | - | - | - | -8 |
|---|
| Adjustments For Loss From Modification Of Warrants Terms As Part Of A New Issuance. | - | - | - | - | - | - | 1 | - |
|---|
| Issuance costs in respect of warrants | - | - | - | - | - | - | 2 | 1 |
|---|
| Exchange differences and revaluation of bank deposit | - | - | - | - | - | - | - | -0 |
|---|
| Total adjustments in respect of income and expenses not involving cash flow | -3 | 3 | 4 | 19 | 34 | 34 | -44 | -3 |
|---|
| Decrease (increase) in trade receivables | -1 | 1 | -0 | -27 | -3 | -3 | 32 | 0 |
|---|
| Decrease in prepaid expenses and other receivables | - | - | - | - | - | - | - | 2 |
|---|
| Decrease in inventories | -1 | -0 | -1 | -5 | -8 | 4 | 2 | 1 |
|---|
| Decrease in accounts payable | 5 | -1 | 1 | 7 | 0 | -7 | -1 | -2 |
|---|
| Decrease in accrued expenses and other liabilities | 3 | 1 | -1 | 19 | -3 | -3 | -13 | 3 |
|---|
| Increase (decrease) in allowance for deductions from revenue | - | - | - | 17 | 12 | 17 | -37 | -1 |
|---|
| Total changes in assets and liability items | -4 | -1 | 2 | -8 | 1 | -8 | 16 | -2 |
|---|
| Net cash used in operating activities | -45 | -34 | -41 | -49 | -65 | -29 | -36 | -9 |
|---|
| Purchase of fixed assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
|---|
| Change in investment in current bank deposits | - | - | - | - | - | - | 0 | - |
|---|
| Net cash provided by (used in) investing activities | -19 | 5 | 5 | -36 | -8 | 8 | 0 | -0 |
|---|
| Proceeds from issue of ordinary shares | - | - | - | 24 | 79 | 24 | 14 | 8 |
|---|
| Repayment of payable in respect of intangible asset purchase | - | 1 | - | - | 7 | 11 | 7 | - |
|---|
| Decrease in restricted cash | - | - | - | 4 | - | - | 15 | 1 |
|---|
| Payment of principal with respect to lease liabilities | - | - | 1 | 2 | 2 | 1 | 1 | 1 |
|---|
| Net cash provided by financing activities | 26 | 42 | 36 | 84 | 73 | 11 | 21 | 8 |
|---|
| DECREASE IN CASH AND CASH EQUIVALENTS | -38 | 13 | -0 | 0 | 0 | -9 | -14 | -1 |
|---|
| EXCHANGE DIFFERENCES ON CASH AND CASH EQUIVALENTS | 0 | -0 | 0 | 0 | -0 | -0 | -0 | 0 |
|---|
| Supplemental Information Interest Received in Cash | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 |
|---|
| Supplemental Information Interest Paid In Cash | - | - | 0 | 7 | 11 | 8 | 0 | 0 |
|---|
| Decrease In Lease Liability From Early Termination Of Lease | - | - | - | - | - | 1 | 5 | 0 |
|---|
| Decrease in Intangible asset | - | - | - | - | - | - | -60 | - |
|---|
| Decrease in Inventories | - | - | - | - | - | - | -4 | - |
|---|
| Decrease in Payable in respect of Intangible asset | - | - | - | - | - | - | 5 | - |
|---|
| Decrease in Borrowing | - | - | - | - | - | - | 115 | - |
|---|
| Gains from the transfer of the rights in Movantik and extinguishment of debt obligations | - | - | - | - | - | - | 56 | - |
|---|